Non-degrading Swellable Polymer Hydrogels for Intraocular Shunts

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current intraocular shunts made from glutaraldehyde crosslinked porcine gelatin degrade over time due to tissue growth and fluid exposure, leading to inflammation, brittleness, and eventual failure, necessitating repeated treatments for glaucoma management.

Innovation Solution

Development of non-degrading swellable polymer hydrogels with alternating quaternary and secondary carbon atoms in the polymer backbone, which resist oxidation, hydrolysis, and embrittlement, allowing the shunts to swell upon hydration without degrading, thus maintaining biostability and functionality.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If a shunt is made from glutaraldehyde crosslinked porcine gelatin to enable swelling into place, then the shunt can be inserted through small needles and seal effectively, but the shunt degrades over time due to tissue growth and fluid exposure, leading to inflammation and eventual failure

Engineering Contradiction:
Improveswelling into placeVSAvoidbiostability
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent changes the chemical parameters of the polymer material from natural gelatin to synthetic polymers with controlled backbone structures (alternating quaternary and secondary carbon atoms). This parameter change enables the material to maintain both swelling capability and resistance to degradation, resolving the contradiction between ease of operation and reliability

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite polymer structures combining hydrophilic and hydrophobic segments in alternating patterns. This composite structure allows the material to swell when exposed to aqueous environments while maintaining structural integrity and resistance to enzymatic degradation, simultaneously achieving both swelling functionality and long-term biostability

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If a shunt is made from collagen to enable biocompatibility, then the shunt is well-tolerated by tissue, but the shunt becomes brittle and fragile, breaking off when manipulated and requiring eventual replacement

Engineering Contradiction:
Improvetissue compatibilityVSAvoidmechanical integrity
Core Design Contradiction:
Object-affected harmful factorsVSStrength

Solution Approach 1:

The patent fundamentally changes the chemical structure from natural collagen to synthetic polymers with alternating quaternary and secondary carbon atoms. This structural parameter change eliminates the brittleness and fragility inherent in collagen while maintaining biocompatibility, allowing the shunt to withstand manipulation and long-term use without breaking

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a permanent, non-disposable shunt by using degradation-resistant polymer backbones. Unlike collagen shunts that eventually become brittle and require replacement, the synthetic polymer shunts maintain mechanical integrity indefinitely, eliminating the need for periodic replacements and reducing long-term treatment costs

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Reliability

If a shunt is designed to swell in place to seal between needle track and shunt, then effective sealing is achieved, but the shunt generates byproducts that provoke inflammation

Engineering Contradiction:
Improvesealing effectivenessVSAvoidinflammation
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and eliminates the problematic degradation-byproduct generation mechanism by using synthetic polymers with stable backbones that do not undergo hydrolysis or enzymatic degradation. The sealing function is retained through physical swelling, while the harmful chemical degradation reactions are completely removed from the system

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the swelling mechanism from a potentially harmful degradation process into a beneficial physical expansion process. The polymer swells through water absorption without breaking down, transforming what could be a source of inflammatory byproducts into a clean, biocompatible sealing mechanism

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The hydrogel-based intraocular shunts effectively maintain their structural integrity and functionality within the eye, reducing the need for frequent replacements and minimizing complications associated with degradation, while allowing for precise fitting through small needles for minimally invasive procedures.

Implementation Method 1

non-degrading swellable polymer hydrogels... allowing the shunts to swell upon hydration

Methodology Applied
Scientific EffectHydration: Hydrates

Implementation Method 2

The hydrogel-based intraocular shunts effectively maintain their structural integrity and functionality

Methodology Applied
Scientific EffectHydrogel swelling: Hydrogel

Implementation Method 3

non-degrading swellable polymer hydrogels with alternating quaternary and secondary carbon atoms in the polymer backbone, which resist oxidation, hydrolysis, and embrittlement

Methodology Applied
Scientific EffectOxidation resistance: Oxidation

Implementation Method 4

non-degrading swellable polymer hydrogels with alternating quaternary and secondary carbon atoms in the polymer backbone, which resist oxidation, hydrolysis, and embrittlement

Methodology Applied
Scientific EffectHydrolysis resistance: Hydrolysis

Data Source

PatentEP3975951B1Non-degrading swellable polymers as materials for biomedical devices
Publication Date: 2024.07.17 INNFOCUS INC
  • EP3975951B1 patent drawingFigure 1A~1B
  • EP3975951B1 patent drawingFigure 2
  • EP3975951B1 patent drawingFigure 3

AI summary

Disclosed herein are medical devices, such as intraocular shunts, that are made from materials comprising non-degradable, swellable polymer hydrogels, and methods of making and using the same.